Pros and cons of GLP-1 agonists and DPP-IV inhibitors

被引：0

作者：

Toft, Anders Dyhr ^{[1
]}

机构：

[1] Novo Nordisk AS, Virum, Denmark

来源：

IDRUGS | 2007年 / 10卷 / 09期

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：606 / 609

页数：4

共 50 条

[1] Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: For GLP-1/DPP-IV inhibitors
Kumar, Ajay
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2012, 28 : 21 - 25
[2] GLP-1 AND DPP-IV IN TYPE 1 DIABETES
Dejgaard, T.
DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 : A4 - A4
[3] Incretin-based antidiabetics: GLP-1 mimetics and DPP-IV inhibitors
Gallwitz, B.
DIABETOLOGIE UND STOFFWECHSEL, 2008, 3 (04) : 234 - +
[4] GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors
Ahrén B.
Current Diabetes Reports, 2007, 7 (5) : 340 - 347
[5] Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors
Holst, JJ
DIPEPTIDYL AMINOPEPTIDASES IN HEALTH AND DISEASE, 2003, 524 : 263 - 279
[6] Clinical use of GLP-1 agonists and DPP4 inhibitors
Tuch, Bernard E.
PANCREATOLOGY, 2016, 16 (01) : 8 - 9
[7] DPP-IV inhibitors
Holt, Richard I. G.
DIABETES OBESITY & METABOLISM, 2006, 8 (06): : 716 - 716
[8] Evaluation of the Serum Levels of the Incretins (GLP-1 and GIP) and DPP-IV in Crohn's Disease
Magro, Daniela
Calixto, Antonio
Vasques, Ana Carolina
Martinez, Carlos Augusto
Rossi, Debora Helena
Geloneze, Bruno
Pareja, Jose
Coy, Claudio
INFLAMMATORY BOWEL DISEASES, 2016, 22 : S58 - S58
[9] Acute DPP-IV Inhibition Induces Vascular Relaxation Via GLP-1 Independent Pathways
Shah, Zubair I.
Pineda, Colleen A.
Ying, Zhekang
Kampfrath, Thomas
Shah, Nilay
Deiuliis, Jeffrey
Sun, Qinghua
Rajagopalan, Sanjay
DIABETES, 2010, 59 : A175 - A175
[10] Nonlinear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects
Dai, Haiqinq
Gustavson, Stephanie M.
Calle, Roberto A.
Hirshberg, Boaz
DIABETES, 2007, 56 : A135 - A136

← 1 2 3 4 5 →